TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, A Potential First-in-Class Treatment for Migraine Portfolio News / By Libby Nunan TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, A Potential First-in-Class Treatment for Migraine Read More »
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer Portfolio News / By Libby Nunan Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer Read More »
Tortugas Neuroscience Announces Positive Phase 2b Results for Obuprazine (TRTL-107) in Schizophrenia Demonstrating Broad Symptom Improvement and Rapid Onset Portfolio News / By Libby Nunan Tortugas Neuroscience Announces Positive Phase 2b Results for Obuprazine (TRTL-107) in Schizophrenia Demonstrating Broad Symptom Improvement and Rapid Onset Read More »
Atavistik Bio to Present at the Cure HHT 16th International Scientific Conference Portfolio News / By Libby Nunan Atavistik Bio to Present at the Cure HHT 16th International Scientific Conference Read More »
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development Portfolio News / By Libby Nunan ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development Read More »
TriGemX Bio Announces $94M Financing and Initiation of Phase 3 Trials for Elismetrep, A Potential First-in-Class Treatment for Migraine Portfolio News / By Libby Nunan TriGemX Bio Announces $94M Financing and Initiation of Phase 3 Trials for Elismetrep, A Potential First-in-Class Treatment for Migraine Read More »
Atavistik Bio Announces Strategic Research Collaboration with Roche to Discover and Develop Novel Allosteric Therapeutics Portfolio News / By Libby Nunan Atavistik Bio Announces Strategic Research Collaboration with Roche to Discover and Develop Novel Allosteric Therapeutics Read More »
Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical Development Portfolio News / By Libby Nunan Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical Development Read More »
A2 Biotherapeutics Announces Findings from DENALI-1 Study of A2B395 Precision CAR T-Cell Therapy for Patients with Solid Tumors Expressing EGFR Portfolio News / By Libby Nunan A2 Biotherapeutics Announces Findings from DENALI-1 Study of A2B395 Precision CAR T-Cell Therapy for Patients with Solid Tumors Expressing EGFR Read More »
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Portfolio News / By Libby Nunan Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Read More »
